Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Diagnostic
- Drugs
- Cancer
- Disease
- Biotechnology
- Diagnostic Substances
- Medical
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 773
Licensor Invention record nº 554 and any developments, ideas, know-how, trade secrets, data information of the Licensor in the field of tumor markers, and/or the related intellectual property rights in any of the foregoing including without limitation patent applications and patent applications made of a part thereof, already existing before the Effective Date, any patents based thereon, any divisional, continuations, continuations-in-part, reexaminations or reissues thereof as well as certificates of addition and utility models, and any and all patents granted thereon, including the patent application No. EP 09 008 679.4 entitled Diagnostic method for predicting the risk of cancer recurrence based on Histone macro H2A isoforms.
IPSCIO Record ID: 5926
Licensee entered into a License and Technology Licensing Agreement with a University's Cancer Center to commercialize technology developed for cancer detection in animals and humans based on a tumor marker known as p65 which has been demonstrated to show elevated levels in the blood of canine and human cancer patients.
'Diagnostic and Premonitoring Uses of a 65 kDa Tumor-Associated Protein in Com- panion and Domestic Animal Malignancy,' U.S. Patent No. 5,411,868, Issued May 2, 1995; Inventors: Margaret Hanausek-Waluszek; Lezlee Coghlan.
'Tumor Marker Protein for Cancer Risk Assessment,: U.S, Patent No. 5,773,215, Issued June 30, 1998, Inventors: Margaret Hanausek-Walaszek; Thomas J. Slap; and Zbigniew Walaszek.
IPSCIO Record ID: 203487
Licensor Patent Rights shall mean, collectively, (a) all patents and patent applications listed and any foreign counterparts claiming priority therefrom; (b) all patent applications heretofore or hereafter filed in any country which claim (and only to the extent they claim) the Licensor Materials and Information or the use thereof; (c) all patents that have issued or in the future issue from any of the foregoing patent applications, including without limitation utility, model and design patents and certificates of invention; and (d) all divisionals, continuations, continuations-in-part,reissues, reexamination certificates or renewals from, extensions of or additions to any such patents or patent applications. Notwithstanding the foregoing, Licensor Patent Rights shall not include any Patent Rights that are within the Licensee Patent Rights, the Joint Patent Rights or the Properdin Antibody Patent Rights.
Patent Application Pending: US 09/138,723
Licensor Know-How shall mean all Know-How developed or acquired by Licensor solely or jointly with a Third Party that is related to Properdin Antibodies.
Joint Patent Rights shall mean all Patent Rights that claim Joint Inventions.
Joint Know-How shall mean Know-How developed or acquired jointly by employees or agents of both Licensor and Licensee as a result of their collaboration under the 1999 Agreement or under this Agreement; provided that such Know-How does not include subject matter within the Licensee Materials and Information, the Licensor Materials and Information or the Properdin Antibody Materials and Information.
Licensor Materials and Information shall mean, collectively, (a) the Antigen; (b) all reagents, samples and other chemical or biological materials regarding the Antigen which resulted or is otherwise derived from use of the Antigen under the 1999 Agreement or which results or is otherwise derived from use of the Antigen under this Agreement; and (c) all information (and all tangible and intangible embodiments thereof) regarding the foregoing, irrespective of inventorship, which is disclosed by Licensor to Licensee hereunder or which resulted or is otherwise derived from use of the Antigen under the 1999 Agreement or which results or is otherwise derived from use of the Antigen pursuant to this Agreement. Notwithstanding the foregoing, Licensor Materials and Information shall not include subject matter within the Licensee Materials and Information or the Properdin Antibody Materials and Information.
IPSCIO Record ID: 4690
